Serum Apelin and Obesity-Related Complications in Egyptian Children
DOI:
https://doi.org/10.3889/oamjms.2018.312Keywords:
Apelin, Obesity, Children, Metabolic syndromeAbstract
BACKGROUND: The rapidly increasing prevalence of childhood obesity became a major burden on health worldwide, giving an alarm to clinicians and researchers. Adipocytes act as an active endocrine organ by releasing plenty of bioactive mediators (adipokines) that play a major role in regulating metabolic processes. Apelin is a recently identified adipokine that is expressed in adipocytes.
AIM: The current work aimed to uncover the relation between serum apelin and childhood obesity and its related complications as hypertension and hyperglycemia
METHOD: A group of 50 obese and 31 non-obese; sex- and age-matched children were enrolled in our study with a mean age of (9.5 ± 2.1) and (8.7 ± 1.3) respectively. Anthropometric measurements, blood pressure, were assessed in all studied participants, we also determined the lipid profile, serum insulin, fasting blood glucose (FBG) level, HOMA-IR and serum apelin.
RESULTS: Obese children had higher levels of HbA1c, FBG, serum insulin, HOMA-IR, total cholesterol, triglycerides, low-density lipoprotein (LDL) and diastolic blood pressure (DBP Z-score); compared to controls (all P < 0.05). Apelin was significantly higher in obese children versus controls and correlated positively with BMI Z-Score (P = 0.008), DBP Z-Score (P = 0.02), cholesterol, TG (both P = 0.02), serum insulin (P = 0.003), FBG and HOMA-IR (both P = 0.001). Linear regression analysis showed that FBG was the most effective factor in predicting the level of serum apelin (P = 0.04).
CONCLUSION: This work supports the hypothesis that apelin may have a crucial role in the pathogenesis of health hazards related to obesity in children including insulin resistance, hypertension and a higher risk of occurrence of metabolic syndrome.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Caprio S. Insulin resistance in childhood obesity. Journal of pediatric endocrinology & metabolism: JPEM. 2002; 15:487-92. PMid:12017221
Kwiterovich PO, Jr. Recognition and management of dyslipidemia in children and adolescents. Journal of Clinical Endocrinology and Metabolism. 2008; 93:4200–4209. https://doi.org/10.1210/jc.2008-1270 PMid:18697860
Weiss R, Kaufman FR. Metabolic complications of childhood obesity: identifying and mitigating the risk. Diabetes Care. 2008; 31(Suppl 2): 310–316. https://doi.org/10.2337/dc08-s273 PMid:18227502
Arslanian S. Type 2 diabetes in children: clinical aspects and risk factors. Hormone Research. 2002; (Suppl 1):19–28. https://doi.org/10.1159/000053308
Mattsson N, Ro¨nnemaa T, Juonala M, Viikari JS, Raitakari OT. Childhood predictors of the metabolic syndrome in adulthood. The Cardiovascular Risk in Young Finns Study. Annals of Medicine. 2008; 40(7):254–252. https://doi.org/10.1080/07853890802307709 PMid:18728920
Pietrobelli A, Espinoza MC, De Cristofaro P. Childhood obesity: looking into the future. Angiology. 2008; (Suppl 2):30–33. https://doi.org/10.1177/0003319708318788 PMid:18504263
Odegaard JI, Chawla A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science. 2013; 339:172-177. https://doi.org/10.1126/science.1230721 PMid:23307735 PMCid:PMC3725457
Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med. 2008; 14:741-751. https://doi.org/10.2119/2008-00058.Rabe PMid:19009016 PMCid:PMC2582855
Bays HE. "Sick fat," metabolic disease, and atherosclerosis. Am J Med. 2009; 122: S26-37. https://doi.org/10.1016/j.amjmed.2008.10.015 PMid:19110085
Blüher M. Adipose tissue dysfunction in obesity. Exp Clin Endocrinol Diabetes. 2009; 117: 241-250. https://doi.org/10.1055/s-0029-1192044 PMid:19358089
Castan-Laurell I, Dray C, Knauf C, Kunduzova O, Valet P. Apelin, a promising target for type 2 diabetes treatment? Trends in Endocrinology and Metabolism. 2012; 23:234–241. https://doi.org/10.1016/j.tem.2012.02.005 PMid:22445464
Boucher J, Masri B, Daviaud D, Gesta S, Guigné C, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology. 2005; 146:1764-1771. https://doi.org/10.1210/en.2004-1427 PMid:15677759
Sabry RN, El Wakeel MA, El-Kassas GM, Amer AF, El Batal WH, El-Zayat SR. Serum Apelin: A New Marker of Early Atherosclerosis in Children with Type 1 Diabetes Mellitus. Open Access Maced J Med Sci. 2018; 6(4):613-617. https://doi.org/10.3889/oamjms.2018.144 PMid:29731925 PMCid:PMC5927488
Tatemoto K, Takayama K, Zou MX, Kumaki I, Zhang W, et al. The novel peptide apelin lowers blood pressure via a nitric oxide- dependent mechanism. Regulatory Peptides. 2001; 99:87–92. https://doi.org/10.1016/S0167-0115(01)00236-1
Szokodi I, Tavi P, Foldes G, Voutilainen-MyllylaS, Iives M, et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circulation Research. 2002; 91:434–440. https://doi.org/10.1161/01.RES.0000033522.37861.69 PMid:12215493
Taheri S, Murphy K, Cohen M, Sujkovic E, Kennedy A, et al. The effects of centrally administered apelin-13 on food intake, water intake and pituitary hormone release in rats. Biochemical and Biophysical Research Communications. 2002; 291:1208–1212. https://doi.org/10.1006/bbrc.2002.6575 PMid:11883945
Reaux-Le Goazigo A, Alvear-Perez R, Zizzari P, Epelbaum J, BLuet-Pajot MT, et al. Cellular localization of apelin and its receptor in the anterior pituitary: evidence for a direct stimulatory action of apelin on ACTH release. American Journal of Physiology, Endocrinology, and Metabolism. 2007; 292:E7–15. https://doi.org/10.1152/ajpendo.00521.2005 PMid:16896162
Machura E, Szczepanska M, Ziora K, Ziora D, Swietochowska E, et al. Evaluation of adipokines: apelin, visfatin, and resistin in children with atopic dermatitis. Mediators of Inflammation 2013; 2013.
Cekmez F, Cekmez Y, Pirgon O, Canpolat FE, Aydoniz S, et al. Evaluation of new adipocytokines and insulin resistance in adolescents with polycystic ovary syndrome. European Cytokine Network. 2011; 22:32–37. PMid:21411410
Hiernaux J, Tanner JM. Growth and physical studies. In: Human Biology: A guide to field methods. Eds. Weiner JS, Lourie SA, IBP. London, Blackwell Scientific Publications. Oxford: U.K., 1969. PMid:5403554
WHO. World Health Organization Anthroplus for personal computers. Software for assessing growth of the world's children and adolescents, 2007. http://www.who.int/growthref/tools/en/
WMGRS. Members of the WHO Multicenter Growth Reference Study Group. WHO child growth standards: length/height-for age, weight-for-age, weight-for-length, weight-for-height and body mass index for age: methods and development. In: WHO Press, editors. WHO Child Growth Standards. Available in http://www.who.int/childgrowth/standards/Technical_report.pdf.
Fernandez J, Redden D, Pietrobelli A, Allison D. Waist circumference percentiles in nationally representative samples of African-American, European-American, and Mexican-American children and adolescents. Journal of Pediatrics. 2004; 145(4):439-444. https://doi.org/10.1016/j.jpeds.2004.06.044 PMid:15480363
Wühl E, Witte K, Soergel M, Mehls O, Schaefer F; German Working Group on Pediatric Hypertension. Distribution of 24-h ambulatory blood pressure in children: Normalized reference values and role of body dimensions. J Hypertens. 2002; 20(10):1995-2007. https://doi.org/10.1097/00004872-200210000-00019 PMid:12359978
Principe A, Melgar-Lesmes P, Fernández-Varo G, del Arbol LR, Ros J, et al. The hepatic apelin system: a new therapeutic target for liver disease. Hepatology. 2008; 48:1193-1201. https://doi.org/10.1002/hep.22467 PMid:18816630
Keskin M, Kurtoglu S, Kendirci M, Atabek ME, Yazici C. Homeostasis Model Assessment Is More Reliable Than the Fasting Glucose/Insulin Ratio and Quantitative Insulin Sensitivity Check Index for Assessing Insulin Resistance Among Obese Children and Adolescents. Pediatrics. 2005; 115:e500. https://doi.org/10.1542/peds.2004-1921 PMid:15741351
Mirzaei K, Hossein-Nezhad A, Aslani S, Emamgholipour S, Karimi M, et al. Energy Expenditure Regulation Via Macrophage Migration Inhibitory Factor (MIF) in Obesity and In Vitro Anti-MIF Effect of Alpinia Officinarum Hance Extraction. Endocr Pract. 2011; 18:39-48. https://doi.org/10.4158/EP11116.OR PMid:21803717
Van Pelt RE, Jankowski CM, Gozansky WS, Schwartz RS, Kohrt WM. Lower-body adiposity and metabolic protection in postmenopausal women. J Clin Endocrinol Metab. 2005; 90:4573-4578. https://doi.org/10.1210/jc.2004-1764 PMid:15886255 PMCid:PMC2819700
Gómez-Ambrosi J, Salvador J, Silva C, Pastor C, Rotellar F, Gil MJ, Cienfuegos JA, Frühbeck G. Increased cardiovascular risk markers in obesity are associated with body adiposity: role of leptin. Thromb Haemost. 2006; 95(6):991-6. https://doi.org/10.1160/TH06-02-0079 PMid:16732378
Garcia-Diaz D, Campion J, Milagro F, et al. Adiposity dependent apelin gene expression: relationships with oxidative and inflammation markers. Mol Cell Biochem. 2007; 305:87–94. https://doi.org/10.1007/s11010-007-9531-5 PMid:17594060
Higuchi K, Masaki T, Gotoh K, Chiba S, Katsuragi I, Tanaka K, Kakuma T, Yoshimatsu H. Apelin, an APJ receptor ligand, regulates body adiposity and favors the messenger ribonucleic acid expression of uncoupling proteins in mice. Endocrinology. 2007; 148:2690–2697. https://doi.org/10.1210/en.2006-1270 PMid:17347313
Frier BC, Williams DB, Wright DC. Mitochondrial content the effects of apelin treatment on skeletal muscle. Am J Physiol Regul Integr Comp Physio. 2009; 297:R1761–R1768. https://doi.org/10.1152/ajpregu.00422.2009 PMid:19793954
Ba HJ, Chen HS, Su Z, Du ML, Chen QL, Li YH, Ma HM. Associations between serum apelin-12 levels and obesity-related markers in Chinese children. PLoS One. 2014; 9(1):e86577. https://doi.org/10.1371/journal.pone.0086577 PMid:24475149 PMCid:PMC3903556
Sheibani S, Hanachi P, Refahiat MA. Effect of aerobic exercise on serum concentration of apelin, TNFa and insulin in obese women. Iran J Basic Med Sci. 2012; 15(6):1196–1201. PMid:23653851 PMCid:PMC3646232
Reinehr T, Woelfle J, Roth CL. Lack of association between apelin, insulin resistance, cardiovascular risk factors, and obesity in children: a longitudinal analysis. Metabolism Clinical and Experimental. 2011; 60:1349–1354. https://doi.org/10.1016/j.metabol.2011.02.005 PMid:21489579
Li L, Yang G, Li Q, Tang Y, Yang M, et al. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Experimental and Clinical Endocrinology & Diabetes. 2006; 114:544–548. https://doi.org/10.1055/s-2006-948309 PMid:17177135
Sorhede WM, Magnusson C, Ahren B. The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice. Regul Pept. 2005; 131:12–17. https://doi.org/10.1016/j.regpep.2005.05.004 PMid:15970338
Assaad SN, El-Aghoury AA, El-Sharkawy EM, Azzam EZ, Salah MA. Study of serum apelin and its relation to obesity-associated hypertension. Egyptian Journal of Obesity, Diabetes and Endocrinology. 2015; 1(1):28. https://doi.org/10.4103/2356-8062.159990
Rittig K, Hildebrandt U, Thamer C, Staiger H, Peter A, Stefan N, et al. Apelin serum levels are not associated with early atherosclerosis or fat distribution in young subjects with increased risk for type 2 diabetes. Exp Clin Endocrinol Diabetes. 2011; 119:358–361. https://doi.org/10.1055/s-0030-1268466 PMid:21264801
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0
